Abstract
Abstract in English, Chinese, Chinese Oral squamous cell carcinoma (OSCC) is a prevalent malignant tumor affecting the head and neck region (Leemans et al., 2018). It is often diagnosed at a later stage, leading to a poor prognosis (Muzaffar et al., 2021; Li et al., 2023). Despite advances in OSCC treatment, the overall 5-year survival rate of OSCC patients remains alarmingly low, falling below 50% (Jehn et al., 2019; Johnson et al., 2020). According to statistics, only 50% of patients with oral cancer can be treated with surgery. Once discovered, it is more frequently at an advanced stage. In addition, owing to the aggressively invasive and metastatic characteristics of OSCC, most patients die within one year of diagnosis. Hence, the pursuit of novel therapeutic drugs and treatments to improve the response of oral cancer to medication, along with a deeper understanding of their effects, remains crucial objectives in oral cancer research (Johnson et al., 2020; Bhat et al., 2021; Chen et al., 2023; Ruffin et al., 2023). 尽管木犀草素的抗癌作用已在多种肿瘤模型中报道，但关于其在口腔癌中的作用研究鲜少。本研究探讨了木犀草素对口腔癌细胞OC3生长和迁移的影响及其机制。结果表明，木犀草素能够抑制或下调OC3细胞的增殖、细胞周期以及p53-Ser15(P)和polo样激酶1（PLK1）蛋白水平。耗氧率（OCR）和胞外酸化率（ECAR）水平以及ATP产量也显著降低。Transwell试验进一步证实OC3细胞的迁移能力会受到木犀草素的影响。综上，本研究发现木犀草素能抑制口腔癌细胞OC3的增殖，其机制可能与p53-PLK1信号传导下调和细胞能量代谢降低有关。. 尽管木犀草素的抗癌作用已在多种肿瘤模型中报道，但关于其在口腔癌中的作用研究鲜少。本研究探讨了木犀草素对口腔癌细胞OC3生长和迁移的影响及其机制。结果表明，木犀草素能够抑制或下调OC3细胞的增殖、细胞周期以及p53-Ser15(P)和polo样激酶1（PLK1）蛋白水平。耗氧率（OCR）和胞外酸化率（ECAR）水平以及ATP产量也显著降低。Transwell试验进一步证实OC3细胞的迁移能力会受到木犀草素的影响。综上，本研究发现木犀草素能抑制口腔癌细胞OC3的增殖，其机制可能与p53-PLK1信号传导下调和细胞能量代谢降低有关。